SecBot SecBot
PRESS-RELEASE ·Filed Nov 3, 2026

TECH

Bio-Techne Corporation
NEUTRAL
Impact 2/10
Horizonimmediate Processed13d ago WireGlobeNewswire
Press release · Dividend
Actionable Insight • Neutral

The dividend is routine and small relative to market cap. The pending Merck KGaA acquisition is the key catalyst; monitor for shareholder vote and regulatory approvals.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$72.73
T+0 close · Nov 3, 2026 · via day close
Latest settled
+0.10%
T+5 · $72.80 · next T+20 in 16d
Vs SPY
+1.01%
α at T+5
Latest observation
+2.31%
T+7 · FF3 residual α
  1. T+0 · Nov 4 $72.73entry
  2. T+1 · 12d ago −0.10%α +4.31% · $72.66
  3. T+5 · 6d ago +0.10%α +1.01% · $72.80
  4. T+8 · todayOpen
  5. T+20 · in 16d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Bio-Techne declared a quarterly dividend of $0.08 per share, payable November 23, 2026 to holders of record November 13, 2026, contingent on the pending Merck KGaA acquisition not closing before the record date. The dividend is a routine capital return event with no material financial impact.

Key Facts

  • Dividend of $0.08 per share declared for quarter ended September 30, 2026
  • Payable November 23, 2026 to shareholders of record November 13, 2026
  • Dividend contingent on Merck KGaA acquisition not closing before record date
  • Bio-Techne generated over $1.2 billion in net sales in fiscal 2026

Financial Impact

$0.08 per share quarterly dividend; annualized ~$0.32 per share, representing a yield of approximately 0.3% based on current market cap of $11.4B

dividend

Risk Factors

  • Dividend may be cancelled if the Merck KGaA acquisition closes before the record date
  • No material read-through for standalone operations

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
0% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-prn-302928623

Track record

12 reports on TECH

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +2.07% at T+60 after the Jun 25, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 12, 20264d ago 10-Q/A Neutral 1/10 Entry $72.80 Now $72.80 +0.00% settles Dec 14
  2. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $72.66 Now $72.80 +0.19% settles Dec 4
  3. Nov 3, 202613d ago 8-K Neutral 2/10 Entry $72.73 Now $72.80 +0.10% settles Dec 3
  4. Nov 3, 202613d ago Press Release Neutral 2/10 Viewing Entry $72.73 Now $72.80 +0.10% settles Dec 3
  5. Oct 29, 202618d ago Institutional Cluster Bearish 4/10 Entry $72.71 Now $72.80 −0.12% settles Nov 27
  6. Oct 28, 202619d ago 10-K/A Neutral 3/10 Entry $72.71 Now $72.80 +0.12% settles Nov 27
  7. Sep 23, 20267w ago 8-K Bullish 6/10 Entry $72.57 to $72.62 Now $72.80 +0.32% ▲ +0.07% +0.49% vs SPY
  8. Sep 23, 20267w ago Press Release Bullish 6/10 Entry $72.52 to $72.64 Now $72.80 +0.39% ▲ +0.17% −0.52% vs SPY
  9. Aug 12, 202613w ago 8-K Bullish 7/10 No price data
  10. Aug 12, 202613w ago Press Release Neutral 4/10 Entry $72.23 to $72.08 Now $72.80 +0.79% ▼ −0.21% +1.69% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens Wed (11h 58m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026